modelTiclopidine
Extends from Pharmacolibrary.Drugs.ATC.B.B01AC05.
Information
| name: | Ticlopidine | |
| ATC code: | B01AC05 | route: | oral |
| compartments: | 1 | |
| dosage: | 250 | mg |
| volume of distribution: | 40 | L |
| clearance: | 0.5 | L/hr/kg |
| other parameters in model implementation | ||
Ticlopidine is an oral antiplatelet agent formerly used for the prevention of thrombotic stroke and to reduce the risk of heart attack and other cardiovascular events, particularly in patients intolerant to aspirin. Its use is limited today due to adverse effects such as neutropenia and replaced by newer alternatives like clopidogrel.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers, mixed sex, single oral dose.
References
Zhang, L, et al., & Yan, X (2022). Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15-2. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 177 106264–None. DOI:10.1016/j.ejps.2022.106264 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35868434
Yin, T, & Miyata, T (2011). Pharmacogenomics of clopidogrel: evidence and perspectives. Thrombosis research 128(4) 307–316. DOI:10.1016/j.thromres.2011.04.010 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21592545
Ashraf, MW, et al., & Saari, TI (2018). Semimechanistic Population Pharmacokinetic Model to Predict the Drug-Drug Interaction Between S-ketamine and Ticlopidine in Healthy Human Volunteers. CPT: pharmacometrics & systems pharmacology 7(10) 687–697. DOI:10.1002/psp4.12346 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30091858
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)